GRAIL is a clinical diagnostics company founded in 2016 as a spinoff from Illumina, headquartered in Menlo Park, California, with additional offices in Washington, D.C., North Carolina, and the United Kingdom. Its core focus is the development of blood-based multi-cancer early detection (MCED) tests, combining next-generation sequencing, machine learning, and large-scale genomic research to identify cancer at stages when treatment is most likely to succeed.
The company's flagship product, Galleri, is a multi-cancer early detection blood test that screens for over 50 cancer types from a single blood draw. Notably, it covers more than 45 cancer types that currently lack any recommended screening test. GRAIL operates CAP-accredited, CLIA-certified laboratory facilities and runs what it describes as one of the largest clinical study programs in genomic medicine, generating substantial datasets to support its detection technology.
GRAIL brings together scientists, engineers, and physicians across technical domains including next-generation sequencing, population-scale clinical studies, machine learning, software, and automation. The company collaborates with health systems, academic medical centers, and pharmaceutical companies globally.